Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | MMP1 | P03956 | 1/20 | 0.33 |
| ▸ | MMP2 | P08253 | 1/20 | 0.33 |
| ▸ | MMP3 | P08254 | 1/20 | 0.33 |
| ▸ | MMP9 | P14780 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2673508 | 1.00 | ALDH1A1 (0.47) | ALDH1A1USP2LMNAALOX12MAPT | |
| SCHEMBL2673510 | 1.00 | ALDH1A1 (0.47) | ALDH1A1USP2LMNAALOX12MAPT | |
| SCHEMBL21987080 | 0.98 | ALDH1A1 (0.50) | ALDH1A1USP2LMNAALOX12MAPT | |
| SCHEMBL21987011 | 0.98 | ALDH1A1 (0.50) | ALDH1A1USP2LMNAALOX12MAPT | |
| SCHEMBL10583061 | 0.83 | ALDH1A1 (0.49) | ALDH1A1USP2LMNAALOX12MAPT | |
| SCHEMBL22783869 | 0.83 | ALDH1A1 (0.49) | ALDH1A1USP2LMNAALOX12MAPT | |
| SCHEMBL10583065 | 0.83 | ALDH1A1 (0.49) | ALDH1A1USP2LMNAALOX12MAPT | |
| SCHEMBL21987071 | 0.80 | CHRNB2 (0.45) | ALDH1A1USP2LMNAALOX12HPGD | |
| SCHEMBL11407382 | 0.80 | SMN1; SMN2 (0.54) | ALDH1A1USP2LMNAMAPTMMP1 | |
| SCHEMBL11407379 | 0.80 | SMN1; SMN2 (0.54) | ALDH1A1USP2LMNAMAPTMMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 89 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11840528-B2 | Isoxazolyl ether derivatives as GABAA α5 PAM | HOFFMANN-LA ROCHE INC. (US) | 2023-12-12 | — | — | US | disclosed |
| CN-116981672-A | Macrocyclic compounds as CFTR modulators | 爱杜西亚药品有限公司 | 2023-10-31 | — | — | CN | disclosed |
| US-20220411415-A1 | ISOXAZOLYL ETHER DERIVATIVES AS GABA A ALPHA5 PAM | HOFFMANN-LA ROCHE INC. (US) | 2022-12-29 | — | — | US | disclosed |
| EP-4074708-A1 | 1-(4-(ISOXAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-METHYLPROPAN-2-OL DERIVATIVES AND RELATED COMPOUNDS AS IL-7 AND IFN-GAMMA INHIBITORS FOR TREATING AUTOIMMUNE DISEASES AND CHRONIC INFLAMMATION | Immunic AG (DE) | 2022-10-19 | — | — | EP | disclosed |
| EP-3679034-B1 | 1-(4-(ISOXAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-METHYLPROPAN-2-OL DERIVATIVES AND RELATED COMPOUNDS AS IL-7 AND IFN-GAMMA INHIBITORS FOR TREATING AUTOIMMUNE DISEASES AND CHRONIC INFLAMMATION | IMMUNIC AG (DE) | 2022-06-01 | — | — | EP | disclosed |
| EP-3551627-B1 | NEW ISOXAZOLYL ETHER DERIVATIVES AS GABA A ALPHA5 PAM | HOFFMANN LA ROCHE (CH) | 2022-02-16 | — | — | EP | disclosed |
| US-11091471-B2 | Isoxazolyl ether derivatives as GABAA α5 PAM | HOFFMANN-LA ROCHE INC. (US) | 2021-08-17 | — | — | US | disclosed |
| EP-3807269-A1 | NEW ISOXAZOLYL ETHER DERIVATIVES AS GABA A ALPHA5 PAM | F. Hoffmann-La Roche AG (CH) | 2021-04-21 | — | — | EP | disclosed |
| US-20210094945-A1 | NEW ISOXAZOLYL ETHER DERIVATIVES AS GABA A ALPHA5 PAM | HOFFMANN-LA ROCHE INC. (US) | 2021-04-01 | — | — | US | disclosed |
| US-20210061796-A1 | IL-17 and IFN-gamma inhibition for the treatment of autoimmune diseases and chronic inflammation | IMMUNIC AG (DE) | 2021-03-04 | — | — | US | disclosed |
| US-20100216845-A1 | ISOXAZOLES / O-PYRIDINES WITH ETHYL AND ETHENYL LINKER | ROCHE PALO ALTO LLC | 2010-08-26 | — | — | US | disclosed |
| US-20100210651-A1 | ISOXAZOLE-ISOXAZOLES AND ISOXAZOLE-ISOTHIAZOLES | ROCHE PALO ALTO LLC | 2010-08-19 | — | — | US | disclosed |
| US-7612069-B2 | Acyl guanidines as beta-secretase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-11-03 | — | — | US | disclosed |
| US-20090143385-A1 | ISOXAZOLO-PYRIDAZINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-06-04 | — | — | US | disclosed |
| US-20090143371-A1 | ISOXAZOLE-PYRIDINE DERIVATIVES | ROCHE PALO ALTO LLC | 2009-06-04 | — | — | US | disclosed |
| US-7273882-B2 | Aminoacetamide acyl guanidines as β-secretase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-09-25 | — | — | US | disclosed |
| US-20070015754-A1 | Acyl guanidines as beta-secretase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2007-01-18 | — | — | US | disclosed |
| WO-2007002214-A2 | ACYL GUANIDINES AS BETA-SECRETASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-01-04 | — | — | WO | disclosed |
| WO-2007002220-A2 | AMINOACETAMIDE ACYL GUANIDINES AS BETA-SECRETASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-01-04 | — | — | WO | disclosed |
| US-20060287287-A1 | Aminoacetamide acyl guanidines as beta-secretase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2006-12-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11840528-B2 | Isoxazolyl ether derivatives as GABAA α5 PAM | GABRA5, GABRA2, GABRB2 | ALDH1A1 1215/4885USP2 3807/4885LMNA 3204/4885 |
| US-20090143371-A1 | ISOXAZOLE-PYRIDINE DERIVATIVES | GABRA5, GABRA1, CHRNA5 | ALDH1A1 938/4885USP2 3950/4885LMNA 3918/4885 |
| US-20210061796-A1 | IL-17 and IFN-gamma inhibition for the treatment of autoimmune diseases and chronic inflammation | IFNG, IL17A, IFNAR1 | ALDH1A1 1850/4885USP2 3862/4885LMNA 3556/4885 |
| US-20100210651-A1 | ISOXAZOLE-ISOXAZOLES AND ISOXAZOLE-ISOTHIAZOLES | GABRA5, GABRA1, GABRA4 | ALDH1A1 808/4885USP2 4006/4885LMNA 4304/4885 |
| US-20090143385-A1 | ISOXAZOLO-PYRIDAZINE DERIVATIVES | GABRA5, CHRNA5, GABRA1 | ALDH1A1 1301/4885USP2 4433/4885LMNA 2743/4885 |
| US-20220411415-A1 | ISOXAZOLYL ETHER DERIVATIVES AS GABA A ALPHA5 PAM | GABRA5, GABRB1, GABRA1 | ALDH1A1 808/4885USP2 3863/4885LMNA 2024/4885 |
| US-20210094945-A1 | NEW ISOXAZOLYL ETHER DERIVATIVES AS GABA A ALPHA5 PAM | GABRA5, GABRB2, GABRB1 | ALDH1A1 1579/4885USP2 3012/4885LMNA 2624/4885 |
| US-20100216845-A1 | ISOXAZOLES / O-PYRIDINES WITH ETHYL AND ETHENYL LINKER | GABRA5, GABRA1, GABRA4 | ALDH1A1 307/4885USP2 4097/4885LMNA 3530/4885 |
| US-20060287287-A1 | Aminoacetamide acyl guanidines as beta-secretase inhibitors | APP, BACE1, BACE2 | ALDH1A1 2529/4885USP2 1712/4885LMNA 1089/4885 |
| US-20070015754-A1 | Acyl guanidines as beta-secretase inhibitors | BACE1, APP, BACE2 | ALDH1A1 2144/4885USP2 3164/4885LMNA 961/4885 |
| US-11091471-B2 | Isoxazolyl ether derivatives as GABAA α5 PAM | GABRA5, GABRA1, GABRA3 | ALDH1A1 930/4885USP2 4325/4885LMNA 2506/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.